Estradiol (E2) is a female hormone that is produced largely by the ovaries, but also 3 by the adrenal glands, fat and liver. It is present in the circulation of both males and 4 females. Many studies in the literature have described how E2 is beneficial to the 5 body in terms of preventing bone loss, affording protection in ischemia reperfusion 6 injury, relieving symptoms of menopause, maintaining vaginal health, and helping 7 with ovarian failure or hypogonadism. Beneficial effects on the brain have been 8 reported to include protection against memory loss, neuronal degeneration, changes 9 in cognition, mood and behavior. However, the effects of E2 exposure on the 10 neuroendocrine system have not been understood completely. This is because 11 differences in doses, preparation and duration of exposure have produced variable 12 results ranging from beneficial, to no change, or to detrimental. Studies in our lab 13 over the last few years have shown that chronic exposures to low levels of E2 in 14 young rats can produce specific effects on the neuroendocrine system. We have 15 observed that these exposures can induce reproductive senescence, hypertension, 16 anxiety-like behavior, and cause degenerative changes in specific neuronal 17 populations leading to hyperprolactinemia. The purpose of the review is to present 18 evidence from the literature for these effects and to discuss the underlying 19 molecular mechanisms.
Introduction: 28
Estrogens are female hormones that are responsible for the onset and 29 progression of female reproductive cycles and the development of secondary sexual 30 characteristics typical of females. There are three kinds of estrogens in circulation: 31 estrone (E1), estradiol (E2) and estriol (E3). Of these, E2 is present at higher levels, 32
fluctuates throughout the life of females, and much of the endogenous estrogenic 33 activity has been attributed to this hormone. E2 plays important roles in the 34 regulation of reproduction and energy metabolism, and influences a number of 35 other hormones such as thyroid hormones (Santin & Furlanetto 2011) . It is also 36 reported to produce a variety of beneficial effects especially when it is used to 37 restore estrogens in older women or ovariectomized animal models. These effects 38 include preventing bone loss in early postmenopausal women (Cooper et al. 1999) , 39 preventing age-related changes in the skin (Patriarca et al. 2013) , improving insulin 40 sensitivity in ovariectomized animals (Shen et al. 2014) and in postmenopausal 41 women (Raudaskoski et al. 1999) , preventing the incidence of type 2 diabetes early 42 in menopause (Pereira et al. 2015) , and improving cognitive functions after focal 43 ischemia in experimental animals (Soderstrom et al. 2009) 
and in postmenopausal 44
women with Alzheimer's disease (Wharton et al. 2011). 45 There are numerous studies describing the beneficial effects of E2 exposure 46 on the brain and many of these beneficial effects have been observed after acute E2 47 exposures (Bagger et al. 2005) , (Whitmer et al. 2011 ), (Zhang et al. 2018 . However, 48 the effects of chronic E2 exposures have not been explored in great detail. These 49 exposures are more relevant since humans are exposed to a variety of estrogenic 50 regularly cycling animals (Lu et al. 1979) . In other words, rats implanted with E2 120 pellets were continuously exposed to proestrous levels of E2. If we consider the 121 normal aging process in rats, they experience roughly 7 estrous cycles (and 122 therefore 7 days of proestrous) a month. They enter the constant estrous state after 123 8 months of regular cycling (or after 56 days of proestrous). In our studies, the dose 124 of E2 used made animals enter constant estrous after 60 days of exposure (Kasturi 125 et al. 2009 , Gilbreath et al. 2014 . These results suggest that chronic exposure to 126 20ng of E2/day accelerates reproductive aging. 127
Other studies in ovariectomized rats have found that E2 implants can 128 suppress GnRH activation and block the steroid-induced LH surge (Tsai & Legan 129 2001 , Tsai & Legan 2002 . These implants were capable of generating circulating E2 130 levels of 75pg/ml and were kept in place for a maximum of 4 weeks. The steroid-131 induced LH surges began to decrease in amplitude by 2 weeks and were completely 132 absent after 4 weeks of E2 exposure (Tsai & Legan 2002) . These investigators also 133 reported that the reduction in LH levels after E2 exposure did not involve changes in 134 estrogen receptor (ER) expression on GnRH neurons (Legan & Tsai 2003). Further, 135 using the ovariectomized rat model, they demonstrated that acute E2 exposure was 136 capable of suppressing NE release in the hypothalamus (Legan & Callahan 1999) . 137
In an effort to understand the underlying mechanism by which chronic E2 138 exposure decreases NE levels, we have focused on the biosynthetic pathway for NE. 139
Tyrosine Hydroxylase (TH) is the rate-limiting enzyme in the synthesis of NE and 140 dopamine. One means by which noradrenergic activity can be reduced is by 141 nitration of tyrosine residues on TH (Huie & Padmaja 1993 , Ischiropoulos et al. 142 1995 . Peroxynitrite, an oxidant that arises from the reaction of nitric oxide and 143 superoxide anion, gives rise to nitrating species that can nitrate tyrosine moieties on 144 proteins (Radi 2013) . This can lead to inactivation of protein function, particularly 145 of proteins like TH which contain several tyrosine residues in their structure (Ara et 146 al. 1998) . The tyrosine moieties in TH are clustered around the active center of the 147 enzyme (Imam et al. 2001 ) and nitration of the tyrosine residues causes steric 148 hindrance, which, in turn inhibits the activity of this enzyme (Imam et al. 2001) . 149
Thus, measurement of nitration of TH can be used as an indicator of degeneration of 150 noradrenergic neurons. In fact, we have shown that there is a gradual increase in 151 nitration of TH in the MPA with increasing duration of E2 exposure that parallels the 152 reduction in NE levels (Kasturi et al. 2013 ). Therefore, it is possible that E2-induced 153 increase in nitric oxide metabolism in the hypothalamus could cause nitration of TH 154 and lead to a loss of noradrenergic neuronal function. 155
Brain derived neurotrophic factor (BDNF) is another likely candidate to be 156 involved in the neuroendocrine effects of chronic E2 exposure. BDNF is widely 157 distributed throughout the brain including cerebral and cerebellar cortex, 158 hypothalamus, midbrain, hindbrain and the brain stem and is considered to be a 159 protective factor (Hofer et al. 1990 , Wetmore et al. 1990 , Merlio et al. 1992 , Masana 160 et al. 1993 , Viant et al. 2000 . E2 is a potent regulator of BDNF (Singh et al. 1995 , 161 Sohrabji et al. 1995 , Wang & Zheng 1998 , Kenny et al. 2000 , West et al. 2001 , Wu et 162 al. 2004 , Yan et al. 2004 ) since the BDNF gene promoter region has an estrogen 163 responsive element (Amantea et al. 2005) . Moreover, ERs have been identified in 164 BDNF-synthesizing neurons (Miranda et al. 1993) . E2 and BDNF have overlapping 165 actions in the forebrain, and act through common second messengers such as ERK1 166 and ERK 2 (Singh et al. 1999) . BDNF and NE can be co-localized in neurons (Hwang 167 et al. 2013 ) and can influence each others' expression (Juric et al. 2008 , Sakata & 168 Duke 2014 . Therefore, there is a possibility that changes in BDNF expression can 169 affect NE levels and vice versa. In the chronic E2 exposure model, we have found 170 that BDNF levels decrease in specific brain regions such as the amygdala 171 (Balasubramanian et al. 2014) . However, there are no studies exploring the 172 involvement of BDNF in the neuroendocrine regulation of reproductive functions. 173
Further studies are needed to explore the role of BDNF in the regulation of 174 noradrenergic activity in the context of GnRH regulation after chronic E2 exposure. 175
Other possible mechanisms of decreasing NE levels in the MPA involve 176 increasing GABA release locally (Demling et al. 1985 , Sirivelu et al. 2009a , or by 177 increasing cytokine levels which can in turn act on brainstem NE neurons (Sirivelu et 178 al. 2012 ) and inhibit NE synthesis. E2 can directly stimulate cytokine production 179 from a variety of cells including peritoneal macrophages (Calippe et al. 2008) . In 180 our model, E2 exposure elevated IL-1β levels in specific brain regions such as the 181 MPA (unpublished) and the arcuate nucleus. (MohanKumar et al. 2011) . The source 182 of proinflammatory cytokines in our model is not clear. It is likely that E2 acts 183 through its receptors to increase cytokines. These receptors have been identified in 184 specific cell types such as ependymal, endothelial cells, neurons and glial cells in 185 several areas of the hypothalamus and the brain (Langub & Watson 1992 , Paech et 186 al. 1997 , Azcoitia et al. 1999 , Cardona-Gomez et al. 2000 , Donahue et al. 2000 Cytokines such as IL-1β are known to cross the blood brain barrier and inhibit NE 189 synthesis by acting on brain stem noradrenergic neurons (Sirivelu et al. 2009b) or 190 suppress NE release by increasing GABA levels locally in the hypothalamus (Sirivelu 191 et al. 2009a) . Therefore, the cytokines generated locally in response to chronic E2 192 exposure could act similarly. and dopamine turnover in the median eminence drop (Ben-Jonathan et al. 1977 , 211 Rance et al. 1981 , suggesting that the reduction in dopamine levels contribute to 212 the increase in prolactin secretion. E2 is believed to be one of the contributing 213 factors for the increase in prolactin, either by decreasing dopaminergic activity in 214 TIDA neurons or possibly through a direct effect on the anterior pituitary (Raymond 215 et al. 1978 , Heiman & Ben-Jonathan 1982a , Demarest et al. 1984 , Kohama et al. 216 1992 , Lawson et al. 1993 , Maeda et al. 1996 , Csakvari et al. 2008 , Morel et al. 2009 . 217 E2 treatment for up to 10 days produced a dramatic increase in prolactin mRNA and 218 serum prolactin levels (Lawson et al. 1993) . E2 also decreases the number of 219 dopamine binding sites in the anterior pituitary (Heiman & Ben-Jonathan 1982b) . 220
These effects are probably mediated through ERs located on lactotrophs (Keefer et 221 al. 1976) . Although these studies were acute in nature, they provided clues to what 222 might happen during the natural aging process in rats. 223
Female rats enter the constant estrous state when they are 11-12 months of 224 age and they remain in this state for about 6 months. Prolactin levels in the early 225 stages of constant estrous are about 40 ng/ml and increase to around 200 ng/ml 226 towards the end of constant estrous (Goya et al. 1991) . The reason for this several 227 fold increase has been attributed to a reduction in dopamine levels in the median 228 eminence (Sarkar et al. 1984) . Initially, it was believed that the persistent increase 229 in E2 levels in the constant estrous state continuously stimulated prolactin 230 secretion. This, in turn increased dopamine production in TIDA neurons to turn 231 down prolactin production (Simpkins 1983 , Sarkar et al. 1984 . However, with time, 232 the continuous stimulation by prolactin causes TIDA neurons to become exhausted 233 ultimately leading to lower dopamine production (Simpkins 1983 , Sarkar et al. 234 1984 . There are other physiological changes that occur with aging in the 235 hypothalamus leading to the notion that other mechanisms could also be in play. 236
Gliosis is a phenomenon that is commonly observed with aging. E2 exposure is 237 known to increase astrocyte activity specifically in the arcuate nucleus of the 238 hypothalamus where TIDA neuronal cell bodies are located (Kohama et al. 1995 , 239 Stone et al. 1998 . Moreover, glial fibrillary acidic protein (GFAP) that is produced 240 by activated astrocytes has an estrogen responsive element in its promoter region 241 impairs the synthesis of NE, but also drastically affects dopamine production since it 265 is a synthesizing enzyme required for both NE and dopamine (Nakashima et al. 266 2009). We have been able to block this effect in iNOS knockout mice, but not IL-1 267 receptor knockout mice (our unpublished observations), suggesting that iNOS plays 268 a key role in this phenomenon. Besides nitration of TH, dopamine itself is capable of 269 being nitrated. In fact, there is experimental evidence that indicates that significant 270 amounts of dopamine can get nitrated at pH 7 and nitrated dopamine fails to bind to 271 D1 dopamine receptor (Daveu et al. 1997) . These studies indicate that nitric oxide-272 related free radical generation can have a significant impact on aging processes and 273 processes that mimic aging. Table 2 provides a list of studies using various estrogenic preparations and their 291 effects on cardiovascular function. 292
In light of these findings, it was important to understand the effects of 293 chronic E2 exposure on the cardiovascular system. In fact, the dose of E2 used in 294 the chronic exposure model mimicked oral contraceptive use in young women and 295 HRT in older women. Chronic E2 exposure increased systolic and diastolic blood 296 pressure (BP) without affecting heart rate in female rats (Subramanian et al. 2011) . 297
In fact, systolic BP begins to rise 3 weeks after the beginning of E2 exposure 298 (Subramanian et al. 2017) . A number of studies (both basic and clinical) have 299 reported increases in blood pressure in experimental animals and women after 300 varying doses and duration of E2 exposure (Lim et al. 1987 , Woods 1988 , Byrne et 301 al. 1994 , Chasan-Taber et al. 1996 , Olatunji & Soladoye 2006 to E2 (1.5mg, s.c.) have shown beneficial effects on the cardiovascular system both 304 in ovariectomized and experimental hypertensive animals (Brosnihan et al. 1997 , 305 Gimenez et al. 2006 . In these animals, there was a reduction in mean arterial 306 pressure due to reduced synthesis of and response to Angiotensin II (Brosnihan et 307 al. 1997) and an improvement in microvascular density (Gimenez et al. 2006) . 308
Collectively, these findings support the idea that whether E2 exposure is 309 detrimental or beneficial to the cardiovascular system depends largely on the dose, 310 duration of E2 exposure and the age of the animal. In the previous sections, we described the effects of low dose chronic E2 381 exposures on neuroendocrine functions related to reproduction and prolactin 382 secretion and its impact on the development of moderate hypertension. Besides 383 these effects, E2 is also capable of affecting behavior. The most common association 384 is between E2 and mood swings in women. Although mood disorders are common 385 in women of all reproductive ages, the incidence is higher during the luteal phase of 386 menstrual cycle (premenstrual syndrome (PMS) and premenstrual dysphoric 387 disorder (PMDD) and during the perimenopausal period (anxiety and depression). depression (Zandi et al. 2002 , MacLennan et al. 2006 , Gleason et al. 2015 . 417
Neuroimaging studies also found that women who started using HRT around 418 perimenopause had larger hippocampal volume and better memory performance 419 than the never-users (Erickson et al. 2010) (Maki et al. 2011) . One study that 420 investigated the effects of a combination of estrogen and progestogen on verbal 421 memory in women younger than 65 years of age and did not find a significant 422 association with short and long-delay free recall (Maki et al. 2007 ). On the other 423 hand, another study found improvements in verbal memory (Linzmayer et al. 2001) . 424
Based on these studies, a clear consensus does not exist on whether timing of HRT 425 affects its outcomes. Also, some of these studies involve estrogen plus progestin 426 pills, hence the extent to which progesterone contributes to these outcomes needs 427 to be clarified. While the concept of hormonal therapy for menopause is centered 428 around the fact that stabilizing fluctuating estrogen levels will attenuate the adverse 429 outcomes of menopausal transition, perimenopause is also characterized by periods 430 of increased E2 levels. Whether this period of exposure to elevated E2 levels 431 programs the brain for increased susceptibility to anxiety and depression as 432 observed in postmenopausal women needs to be addressed. 433
Other studies have observed variable effects of estrogen on behavior. 434
Factors such as dose and duration of estrogen exposure, presence or absence of 435 ovaries, and age of the animals at the time of exposure might be responsible for the 436 differences observed in terms of anxiogenic versus anxiolytic effects of estrogen 437 treatment (Table 3) . For example, in other rodent studies, the beneficial effects of 438 chronic estrogen treatment (3 weeks) in improving depression was observed only 439 at low doses (0.3-3μg/day) and not at high doses (10μg/day) which produces supra-440 physiological estradiol levels (Okada et al. 1997) . Further, ovariectomized rats 441 displayed increased activity in the open field test only when treated with estrogen 442 for 5 days and not 35 days (Luine et al. 1998) . In some cases, even acute estrogen 443 treatment (0.75μg for 2 days) has been reported to induce depression-like behavior 444 (Galea et al. 2002) . In comparison with all these studies, the dose of estrogen used in 445 our studies was much lower (20 ng of E2/day) and the duration of exposure was 446 much longer (12 wks) (Kasturi et al. 2009 ). This resulted in lower BDNF mRNA and 447 protein levels in the amygdala, but not in the hippocampus (Balasubramanian et al. 448 2014) . In fact, there was downregulation of one specific BDNF exon (exon VI) 449 (Balasubramanian et al. 2014) which has an estrogen responsive element in its 450 structure (Sohrabji et al. 1995) . This was associated with a reduction in dopamine 451 (DA) levels in the amygdala that has been linked to anxiety in humans (Kienast et al. 452 2008) and rodents (Perez de la Mora et al. 2012) . Further studies are needed to 453 determine if chronic E2-induced reduction in BDNF directly influences DA levels, or 454 if DA levels are decreased independent of BDNF action as a result of TH nitration in 455 the amygdala. 456
Conclusions: 457
We need to consider that E2 is a pleiotropic hormone. It could have a 458 number of beneficial effects as numerous studies in the literature indicate. 459
However, it needs to be used in moderation and with caution. Many of these 460 reported beneficial effects have been observed with higher doses of E2 and for 461 varying durations. According to the studies described here, it appears that chronic 462 exposures to low levels of E2 have widespread effects that are deleterious (Fig 1) . 463
These are important to consider since most of the environmental exposures to 464 estrogenic compounds occur at low levels and for prolonged periods of time. Schematic above depicts the effects of chronic low dose E2 exposure on three distinct brain regions: The hypothalamus, brain stem and the limbic system (hippocampus and amygdala). E2-induced glial activation may play a role in both the hypothalamus and the brainstem. Effects on the hypothalamus involve activation of cytokines and oxidative stress-related pathways leading to nitration of tyrosine hydroxylase that results in reduction in NE and DA levels leading to ovulatory failure and mammary/pituitary tumors respectively. Effects on the brain stem involve increasing ET-1 levels and generation of free radicals that may promote endothelial dysfunction or increased sympathetic nerve activity leading to hypertension. Effects on the hippocampus and amygdala may include reduction in BDNF levels and monoamines leading to anxiety. 361x270mm (300 x 300 DPI) 
